Cargando…
MiR-451a promotes cell growth, migration and EMT in osteosarcoma by regulating YTHDC1-mediated m6A methylation to activate the AKT/mTOR signaling pathway
BACKGROUND: Osteosarcoma is the most prevalent primary malignant bone tumor containing mesenchymal cells with poor prognosis. Being a hot spot of anti-tumor therapy researches, AKT/mammalian target of rapamycin (mTOR) signaling pathway could affect various cellular processes including transcription,...
Autores principales: | Cao, Dong, Ge, Shanshan, Li, Mengchun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8842083/ https://www.ncbi.nlm.nih.gov/pubmed/35198364 http://dx.doi.org/10.1016/j.jbo.2022.100412 |
Ejemplares similares
-
miR-451a is underexpressed and targets AKT/mTOR pathway in papillary thyroid carcinoma
por: Minna, Emanuela, et al.
Publicado: (2016) -
Correction: miR-451a is underexpressed and targets AKT/mTOR pathway in papillary thyroid carcinoma
por: Minna, Emanuela, et al.
Publicado: (2018) -
The m6A reader YTHDC1 regulates muscle stem cell proliferation via PI4K–Akt–mTOR signalling
por: Liu, Jin, et al.
Publicado: (2023) -
mTOR: An attractive therapeutic target for osteosarcoma?
por: Ding, Liu, et al.
Publicado: (2016) -
Regulation of Osteoclast Growth and Fusion by mTOR/raptor and mTOR/rictor/Akt
por: Tiedemann, Kerstin, et al.
Publicado: (2017)